-
Jefferies Believes In A Long-Term Upside for RIGL
Wednesday, May 4, 2011 - 8:31am | 94According to Jefferies, Rigel Pharmaceuticals (NASDAQ: RIGL) was in line with their estimate for 1Q Earnings and believes in a long-term upside for RIGL. In the report, Jefferies said, "We continue to believe in the long-term upside for RIGL shares given the potential for new oral rheumatoid...
-
Benzinga's Top Downgrades (VRTX, DGI, KAR, CCC)
Wednesday, May 4, 2011 - 8:17am | 135Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by Brean Murray from "buy" to "hold." VRTX's shares closed at $54.74 yesterday. VRTX's PEG ratio is -1.05. Benchmark Company downgraded DigitalGlobe Inc (NYSE: DGI) from “buy” to “hold.” DGI's stock closed at $28.72 yesterday....
-
Quest Diagnostics Announces Successful Tender Offer and Commencement of a Subsequent Offering Period for Shares of Celera (DGX, CRA)
Wednesday, May 4, 2011 - 8:07am | 237Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that Spark Acquisition Corporation, its wholly owned subsidiary, successfully completed the cash tender offer for all outstanding shares of common stock of...
-
Morgan Stanley Comments On Myriad Genetics Strong 3Q
Wednesday, May 4, 2011 - 7:45am | 121According to Morgan Stanley, Myriad Genetics (NASDAQ: MYGN) saw a strong 3Q. Morgan Stanley said that an unexpected growth mix from oncology acceleration (~14% vs 5-6% in FY1H11) raises questions about sustainability, which will be the primary debate exiting the quarter. “Guidance implies some...
-
Jefferies Has Hold On Genomic Health (GHDX)
Wednesday, May 4, 2011 - 7:39am | 112Jefferies & Co. has a Hold rating and a $29 price target on shares of Genomic Health (NASDAQ: GHDX) following earnings. In a note to clients, Jefferies writes, "Shares of GHDX may consolidate recent gains (+28% YTD vs 8% for S&P 500 and 9% for its clinical IVD peers) on the absence of...
-
Onyx Pharma (NASDAQ: ONXX) Reports EPS of $(0.23) vs. $(0.13) Estimate; Revenues $67.15M vs. $70.36M Estimate
Wednesday, May 4, 2011 - 7:04am | 116Onyx Pharmaceuticals (NASDAQ: ONXX) today reported its financial results for the first quarter 2011. Onyx reported a non-GAAP net loss of $14.2 million, or $0.23 per diluted share, for the first quarter 2011 compared to a non-GAAP net loss of $1.5 million, or $0.02 per diluted share, for the same...
-
CEOWORLD Most Actives Top Healthcare stocks picks on 5/4/11- GENE, SPPI, AMRI, GTXI, AFFX,KV.A, SCLN, CBM, CERS, CEPH, TEVA, THC, JNJ
Wednesday, May 4, 2011 - 6:59am | 1424Gainers (% price change): Genetic Tech. Ltd. (ADR) (GENE) engaged in a diagnostic product business is trading at a price of $8.18, a dramatic change of +2.41 (41.77%) from its previous day's close. Currently, the company has a Market capitalization (total value of a company in the stock market)...
-
Mad Money Lightning Round: Cramer Advises Investors To Buy Gilead Sciences (GILD, NGG, NOG, AA, VOD)
Wednesday, May 4, 2011 - 2:18am | 187On CNBC's Mad Money, Jim Cramer said during the Lightning Round that Gilead Sciences (NASDAQ: GILD) is “one that has to catch up to the rest of the health care sector. I want to buy it." Cramer likes National Grid (NYSE: NGG). He added, “It's a consistent earner with a good yield." For Northern...
-
Myriad Genetics Reports EPS of $0.31 vs. $0.25 Estimate; Revenues $102.4M vs. $98.11M Estimate (MYGN)
Tuesday, May 3, 2011 - 4:25pm | 22Myriad Genetics (NASDAQ: MYGN) Reports EPS of $0.31 vs. $0.25 Estimate; Revenues $102.4M vs. $98.11M Estimate
-
Cephalon Reports EPS of $1.98 vs. $2.04 Estimate; Revenues $745.1M vs. $750.99M Estimate (CEPH)
Tuesday, May 3, 2011 - 4:11pm | 21Cephalon (NASDAQ: CEPH) Reports EPS of $1.98 vs. $2.04 Estimate; Revenues $745.1M vs. $750.99M Estimate
-
Threshold Pharmaceuticals Presents Positive Preclinical Results at International Myeloma Workshop (THLD)
Tuesday, May 3, 2011 - 4:01pm | 84Threshold Pharmaceuticals, Inc. (Nasdaq: THLD), today announced a presentation of preclinical research on its clinical stage hypoxia-activated prodrug, TH-302, at the 13^th International Myeloma Workshop, being held May 3 to 6, 2011, in Paris, France. The poster presentation describes the efficacy...
-
Top Stocks Picks attracting a lot of interest from traders on 5/3/11: ECTY, GTXI, PRWTD, TSTC, RAH, ISS, ICO, VLCM, DISH, GNMK
Tuesday, May 3, 2011 - 2:51pm | 1366International Coal Group Inc. (NYSE:ICO) a producer of coal in Northern and Central Appalachia markets its coal to a customer base of investment grade electric utilities is trading at a price of $14.45, a dramatic change of +0.02 (0.14%) from its previous day's close. Currently, the company has a...
-
Hearing Luna Innovations Received A Patent Approval (LUNA)
Tuesday, May 3, 2011 - 12:31pm | 45Hearing Luna Innovations Received A Patent Approval (NASDAQ: LUNA) http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=7934424.PN.&OS=PN/7934424&RS=PN/7934424
-
Pharma News; BioSante Pharmaceuticals, Inc. Paving the Way for Sexual Equality for Women! Mr. Stephen M. Simes, President and CEO Gives Insight on the Company's Commitment to Women's Health in the Sexual Dysfunction Market with their Leadi
Tuesday, May 3, 2011 - 11:36am | 1453Point Roberts WA, LINCOLNSHIRE, Ill. May 3, 2011 - (Investorideas.com newswire.com) Investorideas.com, an investor research portal covering leading sectors including biotech stocks and pharma stocks, features an exclusive discussion with Mr. Stephen M. Simes, president and chief executive officer...
-
NASDAQ Stocks Hitting 52-Week Highs (CGNX, IPGP, INCY, OBAF)
Tuesday, May 3, 2011 - 10:10am | 136Cognex Corporation (NASDAQ: CGNX) shares reached $36.45 to create a new 52-week high, before dropping to $36.33, representing a 17% gain. CGNX reported upbeat Q1 profit. IPG Photonics Corporation (NASDAQ: IPGP) shares reached $72 to create a new 52-week high, before falling to $71, representing a...